title: Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome.
abstract: BACKGROUND
  The aggressiveness of fibromatoses is difficult to predict by morphologic analysis. Additional prognostic markers would be helpful for clinical management.
  
  
  METHODS
  Proliferation index (MIB-1), p53, src, retinoblastoma gene protein products, estrogen receptor level, site and depth of lesion were correlated with incidence of recurrence in 52 patients. Superficial (47) and deep (5) fibromatoses were studied. Anatomic sites included the extremities, head, neck, trunk, and pelvis.
  
  
  RESULTS
  Twenty (38%) lesions recurred locally. All five deep lesions recurred, but only 32% of superficial tumors recurred. Mean proliferation index for recurrent lesions was 0.82% and 0.73% for nonrecurrent fibromatoses; no significant differences were observed. Five recurrent lesions (25%) expressed estrogen receptor > 5 fmol/mg as did 31% (10 of 32) of the nonrecurrent lesions. None of the tested specimens expressed src gene product. Eight of the lesions which recurred (40%) contained p53, but only five nonrecurring tumors (16%) expressed p53. One of five deep lesions (20%) expressed p53 and 26% (12 of 47) of superficial tumors expressed p53. Forty-six percent (6 of 13) of recurrent lesions tested were retinoblastoma protein product negative, but only 33.3% (7 of 21) of nonrecurring tumors were retinoblastoma protein product negative.
  
  
  CONCLUSIONS
  Only p53 and depth of lesion were of statistical value for the prediction of recurrence.
authors.affiliation: Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Moffatt
authors.forename: B J
authors.initials: BJ
authors.lastname: Kerns
authors.forename: J M
authors.initials: JM
authors.lastname: Madden
authors.forename: L J
authors.initials: LJ
authors.lastname: Layfield
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D005121:Extremities; D005350:Fibroma / Q000378:metabolism* / Q000473:pathology; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local; D010386:Pelvic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D016160:Retinoblastoma Protein / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D016392:Proto-Oncogene Proteins pp60(c-src)